Nav: Home

Miniature scaffolding could support fight against superbugs

June 13, 2016

Amsterdam, June 13, 2016 - Tiny molecular scaffolding that joins molecules together could be the key to our battle against antibiotic resistance. Research published in Bioorganic & Medicinal Chemistry Letters shows that carbon nanodot scaffolding assembled with small molecules called polyamines can kill some dangerous drug-resistant bacteria, including Acinetobacter baumanii and Klebsiella pneumonia.

According to the World Health Organization, antimicrobial resistance is one of the biggest public health threats we face today; there were about 480,000 new cases of multidrug-resistant tuberculosis in 2013. Standard treatments are failing and there is an urgent need to develop more effective antibiotics.

Scientists working in this area have found that some large positively charged compounds, called polycationic dendrimers, are antimicrobial. The researchers behind the new study, from Winston-Salem State University in the US and Universiti Malaysia Sarawak in Malaysia, have found that adding similar, but smaller polycationic molecules onto a new kind of material called carbon nanodots makes them even better at killing drug-resistant bacteria.

"We urgently need new and better antimicrobial materials if we are to tackle drug-resistant bacteria," said Dr Maria Ngu-Schwemlein, lead author of the study from Winston-Salem State University. "Our study shows that carbon nanodots can serve as a molecular scaffold for building antimicrobial materials; it's exciting because carbon nanodots are relatively easy and cheap to make, they're non-toxic and soluble in water."

Carbon nanodots are tiny particles of carbon that are useful in imaging, sensing, drug delivery and many other applications. They can be made easily from starch and they're non-toxic, making them suitable for use in medicine.

There are chemical groups coating the surface of carbon nanodots that can help control the fluorescence properties of these tiny dots. This coating can also turn the nanodots into a molecular scaffolding for tethering small molecules together to enhance their potential.

The researchers used them to assemble molecules called PAMAM (poly(amidoamines)) together. PAMAM can vary in size, with the larger molecules showing some antimicrobial activity, which is not exhibited by the smaller ones. The team wanted to make the smaller, more flexible molecules better and efficient antimicrobials by attaching them to the carbon nanodot scaffolding, so they built two different molecules: CND-PAM1 and CND-PAM2.

The team tested both versions of CND-PAM and found that they both can kill Escherichia coli and Staphylococcus aureus at very low concentrations. The molecules exhibit greater antimicrobial activity against E. coli, so the researchers tested them against similar bacteria, including drug-resistant strains: Klebsiella pneumonia, Pseudomonas aeruginosa and Acinetobacter baumannii. In the case of K. pneumonia, the molecules were four times more effective at killing the drug-resistant than the normal strain.

The researchers also looked at whether the molecules with scaffolding helped make existing antibiotics work better. Adding CND-PAM1 to the antibiotic tetracycline made it more effective against resistant K. pneumonia, and adding CND-PAM2 to colistin made it four times stronger against A. baumannii.

"We hope our research will lead to more effective antibiotics, and also that it will inspire other researchers to use carbon nanodots as scaffolding for a variety of applications," said Dr. Ngu-Schwemlein.
-end-
Notes for editors

The article is "Carbon nanodots as molecular scaffolds for development of antimicrobial agents," by Maria Ngu-Schwemlein, Suk Fun Chin, Ryan Hileman, Chris Drozdowski, Clint Upchurch and April Hargrove (doi: 10.1016/j.bmcl.2016.02.047). It appears in Bioorganic & Medicinal Chemistry Letters, volume 26, (2016), published by Elsevier.

Copies of this paper are available to credentialed journalists upon request; please contact Elsevier's Newsroom at newsroom@elsevier.com or +31 20 485 2492.

About Bioorganic & Medicinal Chemistry Letters

Bioorganic & Medicinal Chemistry Letters presents preliminary experimental or theoretical research results of outstanding significance and timeliness on all aspects of science at the interface of chemistry and biology and on major advances in drug design and development. The journal publishes articles in the form of communications reporting experimental or theoretical results of special interest, and strives to provide maximum dissemination to a large, international audience.

About Elsevier

Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions -- among them ScienceDirect, Scopus, Elsevier Research Intelligence and ClinicalKey -- and publishes over 2,500 journals, including The Lancet and Cell, and more than 35,000 book titles, including a number of iconic reference works. Elsevier is part of RELX Group, a world-leading provider of information and analytics for professional and business customers across industries. http://www.elsevier.com

Media contact

Annis Moreira
Elsevier
+31 20 485 2770
a.moreira@elsevier.com

Elsevier

Related Pneumonia Articles:

Bacteria in pneumonia attack using bleaching agent
Research shows that bacteria use hydrogen peroxide to weaken the immune system and cause pneumonia.
Many kids with pneumonia get unnecessary antibiotics, chest X-rays
Preschool children with community-acquired pneumonia often receive unnecessary tests and treatment at outpatient clinics and emergency departments, according to a nationally representative study led by Todd Florin, M.D., MSCE, from Ann & Robert H.
Certain psychiatric drugs linked with elevated pneumonia risk
A review of published studies indicates that use of benzodiazepines and benzodiazepine related drugs (BZRDs), which are prescribed to treat various psychiatric diseases, may increase the risk of pneumonia.
Bacterial pneumonia far more dangerous to the heart than viral pneumonia, study finds
Heart complications in patients diagnosed with bacterial pneumonia are more serious than in patients diagnosed with viral pneumonia, according to new research.
Antimicrobial therapy can prevent sepsis in pneumonia patients
Research sheds light on initial phase of infectious disease and potential for prevention of pneumococcal septicaemia.
Research suggests vapers are vulnerable to pneumonia
The vapor from e-cigarettes seems to help pneumonia-causing bacteria stick to the cells that line the airways, according to research published in the European Respiratory Journal.
Pneumonia: Treatment with vaccines instead of antibiotics
A properly functioning immune system is key to resolve bacterial pneumonia.
The end of pneumonia? New vaccine offers hope
A new vaccine under development provoked an immune response to 72 forms of the bacteria that's responsible for pneumonia, sepsis and meningitis.
Antibiotic therapy for nearly 1 in 4 adults with pneumonia does not work
Approximately one in four (22.1 percent) adults prescribed an antibiotic in an outpatient setting (such as a doctor's office) for community-acquired pneumonia does not respond to treatment, according to a new study presented at the 2017 American Thoracic Society International Conference.
Discovery may help patients beat deadly pneumonia
Researchers have identified a hormone that helps fight off a severe form of bacterial pneumonia, and that discovery may offer a simple way to help vulnerable patients.
More Pneumonia News and Pneumonia Current Events

Top Science Podcasts

We have hand picked the top science podcasts of 2019.
Now Playing: TED Radio Hour

Risk
Why do we revere risk-takers, even when their actions terrify us? Why are some better at taking risks than others? This hour, TED speakers explore the alluring, dangerous, and calculated sides of risk. Guests include professional rock climber Alex Honnold, economist Mariana Mazzucato, psychology researcher Kashfia Rahman, structural engineer and bridge designer Ian Firth, and risk intelligence expert Dylan Evans.
Now Playing: Science for the People

#540 Specialize? Or Generalize?
Ever been called a "jack of all trades, master of none"? The world loves to elevate specialists, people who drill deep into a single topic. Those people are great. But there's a place for generalists too, argues David Epstein. Jacks of all trades are often more successful than specialists. And he's got science to back it up. We talk with Epstein about his latest book, "Range: Why Generalists Triumph in a Specialized World".
Now Playing: Radiolab

Dolly Parton's America: Neon Moss
Today on Radiolab, we're bringing you the fourth episode of Jad's special series, Dolly Parton's America. In this episode, Jad goes back up the mountain to visit Dolly's actual Tennessee mountain home, where she tells stories about her first trips out of the holler. Back on the mountaintop, standing under the rain by the Little Pigeon River, the trip triggers memories of Jad's first visit to his father's childhood home, and opens the gateway to dizzying stories of music and migration. Support Radiolab today at Radiolab.org/donate.